| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
| USRE39069 | CHATTEM SANOFI | Multi-layered osmotic device |
May, 2018
(5 years ago) | |
| US6613357 | CHATTEM SANOFI | Osmotic device containing pseudoephedrine and an H1 antagonist |
Dec, 2020
(3 years ago) | |
Allegra-D 24 Hour Allergy And Congestion is owned by Chattem Sanofi.
Allegra-D 24 Hour Allergy And Congestion contains Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride.
Allegra-D 24 Hour Allergy And Congestion has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Allegra-D 24 Hour Allergy And Congestion are:
- US6399632*PED
- US6187791*PED
- US5578610
- US7138524
- US5578610*PED
- US7138524*PED
- US6037353
- US6037353*PED
- USRE39069
- US6613357
Allegra-D 24 Hour Allergy And Congestion was authorised for market use on 24 January, 2011.
Allegra-D 24 Hour Allergy And Congestion is available in tablet, extended release;oral dosage forms.
Allegra-D 24 Hour Allergy And Congestion can be used as relief of symptoms associated with respiratory allergies, swelling of the nasal passages and sinus congestion and pressure in adults and children 12 years of age and older.
The generics of Allegra-D 24 Hour Allergy And Congestion are possible to be released after 25 December, 2020.
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies, swelling of the nasal passages and sinus congestion and pressure in adults and children 12 years of age and older
Dosage: TABLET, EXTENDED RELEASE;ORAL
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION family patents
